| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.krebsbiochem.com | |
| Market Cap | 215.61 Cr. | |
| Enterprise Value(EV) | 389.31 Cr. | 2022-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -16.91 | Trailing Twelve Months Ending 2022-09 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-09 |
| Industry PE | 32.90 | Trailing Twelve Months Ending 2022-09 |
| Book Value / Share | -40.49 | Trailing Twelve Months Ending 2022-09 |
| Price to Book Value | -2.47 | Calculated using Price: 100.00 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 2.16 Cr. | 21,560,586 Shares |
| FaceValue | 10 | |
| Company Profile | ||
| Krebs Biochemicals & Industries (KBIL) was established in the year 1991 as a Public Limited Company with the main objective of establishing commercially viable biotech processes with applications in Medicine, Agriculture Industry. The company has pioneered in the fermentation technology over the last decade. | ||
| 1 Day |
|
-3.89% |
| 1 Week |
|
-5.26% |
| 1 Month |
|
-8.38% |
| 3 Month |
|
-4.76% |
| 6 Month |
|
-11.50% |
| 1 Year |
|
-43.55% |
| 2 Year |
|
-15.65% |
| 5 Year |
|
-30.47% |
| 10 Year |
|
+372.37% |
| 9 years | 2014-09 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | -75.26 | -683.34 | -296.70 | |||||||
| Return on Capital Employed (%) | -3.91 | -4.33 | -25.38 | -27.13 | -28.95 | -35.41 | -56.96 | -40.28 | -57.29 | |
| Return on Assets (%) | -3.19 | -6.44 | -14.60 | -13.46 | -14.38 | -14.92 | -20.91 | -19.36 | -25.51 |
| Particulars | 10 years | 2014-09 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
| Shh. Funds | 4 | 18 | 13 | 1 | -18 | -14 | -25 | -43 | -75 | -87 | |
| Non Curr. Liab. | 23 | 60 | 74 | 89 | 101 | 102 | 116 | 154 | 187 | 216 | |
| Curr. Liab. | 110 | 29 | 30 | 32 | 42 | 55 | 43 | 48 | 78 | 54 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 136 | 107 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 183 | |
| Non Curr. Assets | 98 | 92 | 107 | 109 | 109 | 111 | 115 | 138 | 154 | 158 | |
| Curr. Assets | 39 | 15 | 9 | 13 | 17 | 31 | 19 | 21 | 35 | 25 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 136 | 107 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 183 |
| Particulars | 10 years | 2014-09 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
| Net Sales | 1 | 4 | 34 | 48 | 33 | 54 | 60 | 73 | |||
| Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |
| Total Income | 0 | 0 | 2 | 4 | 34 | 48 | 34 | 54 | 61 | 74 | |
| Total Expenditure | -4 | -5 | -14 | -12 | -41 | -58 | -52 | -71 | -94 | -100 | |
| PBIDT | -4 | -5 | -11 | -8 | -7 | -9 | -18 | -17 | -33 | -26 | |
| Interest | 0 | -4 | -1 | -3 | -5 | -6 | -6 | -6 | -5 | -3 | |
| Depreciation | -2 | -4 | -4 | -4 | -4 | -5 | -5 | -6 | -7 | ||
| Taxation | 0 | ||||||||||
| Exceptional Items | 3 | 0 | 0 | -1 | 0 | ||||||
| PAT | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -36 | |
| Adjusted EPS | -4 | -8 | -12 | -11 | -13 | -12 | -16 | -14 | -21 | -17 |
| Particulars | 10 years | 2013-06 Rs. Cr. | 2014-09 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | -2 | 49 | -45 | -15 | -11 | -6 | 4 | -36 | -15 | -17 | |
| Cash Fr. Inv. | 6 | 0 | -3 | -4 | -5 | -3 | -4 | -10 | -23 | -23 | |
| Cash Fr. Finan. | -4 | -49 | 54 | 13 | 16 | 9 | 17 | 29 | 38 | 40 | |
| Net Change | 0 | 0 | 6 | -6 | 0 | 0 | 17 | -17 | 1 | -1 | |
| Cash & Cash Eqvt | 0 | 0 | 6 | 0 | 0 | 0 | 17 | 0 | 1 | 0 |
|
Mon, 23 Jan 2023
Board Meeting Intimation for Unaudited Financial Results For The 3Rd Quarter And Nine Months Ended December 31 2022 Of The Financial Year 2022-23 KREBS BIOCHEMICALS & INDUSTRIES LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve Pursuant to Regulation 29 read with Regulation 47 of the SEBI (LODR) Regulations 2015 notice is hereby given that meeting of the Board of Directors of the Company will be held on Friday February 03 2023 inter-alia to consider and adopt the Unaudited Financial Results for the 3rd quarter and nine months ended December 31 2022 of the Financial year 2022-23. Further with reference to the above meeting of the Board of Directors we have already informed vide our letter dated December 26 2022 that the trading window for dealing in the securities of the Company by the Insiders as defined under the SEBI (Prohibition of Insider Trading) Regulations 2015 shall remain closed w.e.f December 31 2022 and until 48 hours after the declaration of the Companys unaudited financial results for the 3rd quarter and nine months ended December 31 2022 i.e. February 5 2023. |
|
Wed, 11 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended December 31 2022 |
|
Tue, 03 Jan 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 and based on the intimation received from the Companys Registrar and Transfer Agent (RTA) KFin Technologies Limited we would like to inform that the Company has received a letter from a shareholder regarding loss of share certificates along with a request to issue duplicate share certificates in lieu thereof. |
| Fri, 27 Jan 2023 |
High Delivery Percentage
|
Higher Delivery Quantity
|
Higher Delivery Quantity and Percentage
|
Higher Trade Quantity
|
Higher Trade and Delivery Quantity
|
Equities
M.F.
Sectors